<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written evidence submitted by Public Health England (RaD0016)</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by Public Health England (RaD0016)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We have been asked to </span><span style="font-family:'Times New Roman'; font-size:11pt">submit written evidence to the Science and Technology committee and comment on the </span><span style="font-family:'Times New Roman'; font-size:11pt">four points raised by</span><span style="font-family:'Times New Roman'; font-size:11pt"> the </span><span style="font-family:'Times New Roman'; font-size:11pt">N</span><span style="font-family:'Times New Roman'; font-size:11pt">ational </span><span style="font-family:'Times New Roman'; font-size:11pt">A</span><span style="font-family:'Times New Roman'; font-size:11pt">udit </span><span style="font-family:'Times New Roman'; font-size:11pt">O</span><span style="font-family:'Times New Roman'; font-size:11pt">ffice</span><span style="font-family:'Times New Roman'; font-size:11pt">’s </span><span style="font-family:'Times New Roman'; font-size:11pt">(NAO) </span><span style="font-family:'Times New Roman'; font-size:11pt">review of </span><span style="font-family:'Times New Roman'; font-size:11pt">Research</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and Development funding for science and technology in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> the 2010 and 2013 Spending Reviews.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Our responses are as follows:</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">N</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ational </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">A</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">udit </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Office first point </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Between 1995 and 2011, overall annual spending on R&amp;D increased in real terms by 37% (from just under £20 billion to just under £27 billion) and most of</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> this growth was driven by UK businesses. However, spending declined between 2007 and 2010.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">PHE Response</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We do not have a response available for this point. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">National Audit Office </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">second point</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Between 1995 and 2011, the Government has progressively </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">reduced the amount it spends on undertaking R&amp;D itself through public research institutions but, at the same time, has increased the funding it provides to UK businesses.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 14.2pt; text-align:justify; text-indent:-14.2pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">PHE Response</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We welcome the fact that government funding routed through industry ha</span><span style="font-family:'Times New Roman'; font-size:11pt">s increased.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> In our experience TSB funding has provided an effective incentive for SMEs to undertake R&amp;D in areas of importance to public health, and to collaborate with PHE where access to specialist science or facilities is required.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We have some </span><span style="font-family:'Times New Roman'; font-size:11pt">concerns about the reduction in R&amp;D conducted by Public Sector Research Establishments.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> PSREs have a valuable role to play in addressing issues of societal importance through challenge-led R&amp;D.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Such R&amp;D is typically unattractive to both academic bodies (</span><span style="font-family:'Times New Roman'; font-size:11pt">as it tends to be focused on outcomes rather than publications) and to industry (as it may not offer sufficient commercial return) but government R&amp;D can be a valuable bridge between the two.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The historical perception that the UK is “good at innovation, b</span><span style="font-family:'Times New Roman'; font-size:11pt">ad at exploitation” is no longer universally true, but care must be taken to ensure that incentives exist to translate innovation into practical outcomes and economic growth.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> The inclusion of impact assessment into academic R&amp;D funding allocation decision</span><span style="font-family:'Times New Roman'; font-size:11pt">s has been beneficial, and could usefully be extended to bodies such as the NHS and PSREs which conduct R&amp;D for the benefit of the public but have limited capacity to exploit and disseminate the resulting innovations.</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">National Audit Office </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">third point</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">UK </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">business R&amp;D spending </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">is concentrated</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> in a small number of very large firms, with the pharmaceuticals sector accounting for 28% of total UK business R&amp;D spend. This sector is a key driver of innovation but the UK’s reliance on the sector is also a risk.</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">PHE Response</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">A strong and innovative UK R&amp;D base is an important element in ensuring improved public health in the UK.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> This is true not only in the obvious areas of vaccines and pharmaceuticals, but also in ICT (app</span><span style="font-family:'Times New Roman'; font-size:11pt">lications</span><span style="font-family:'Times New Roman'; font-size:11pt">, software and data analytical </span><span style="font-family:'Times New Roman'; font-size:11pt">tools of relevance to public health), genomics, remote sensing, geographic information, nutrition, and social marketing.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> We would welcome further R&amp;D growth in these areas without neglecting the UK’s leading position in pharmaceutical sciences.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">National </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Audit Office </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">fourth point</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">The UK receives a significant amount of R&amp;D funding from the European Commission:  Framework Programme.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="background-color:#ffffff; margin:0pt; text-align:justify"><a name="top"></a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="background-color:#ffffff; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">PHE Response</span></p><p style="background-color:#ffffff; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The European Commission supports world-class collaborative research and is a major contributor of funding and f</span><span style="font-family:'Times New Roman'; font-size:11pt">uture collaboration opportunities to PHE researchers.  PHE </span><span style="font-family:'Times New Roman'; font-size:11pt">has an excellent international reputation and </span><span style="font-family:'Times New Roman'; font-size:11pt">participates in an extensive network of </span><span style="font-family:'Times New Roman'; font-size:11pt">multidisciplinary collaborative research projects </span><span style="font-family:'Times New Roman'; font-size:11pt">with European public health institutes a</span><span style="font-family:'Times New Roman'; font-size:11pt">nd other European </span><span style="font-family:'Times New Roman'; font-size:11pt">organisations.  </span><span style="font-family:'Times New Roman'; font-size:11pt">These c</span><span style="font-family:'Times New Roman'; font-size:11pt">ollaborations have </span><span style="font-family:'Times New Roman'; font-size:11pt">a number of positive aspects including formal and informal information exchange and pooling of resources, as well as opportunities to benefit from EU funded research outputs and support national research with poole</span><span style="font-family:'Times New Roman'; font-size:11pt">d expertise. </span><span style="font-family:'Times New Roman'; font-size:11pt">The European funding framework (Horizon 2020) will present excellent opportunities for PHE to compete for resources to improve national health protection.  </span></p><p style="margin:0pt; text-align:justify"><span style="color:#00b050; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="color:#00b050; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">August 2013</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>